Plasmapheresis for Thrombotic Microangiopathy Due to a Post-transplant Lymphoproliferative Disorder
Abstract
Open Access
ISSN 2577-5820
© 2022 by the authors; CC BY 4.0 licence
OBM Transplantation , Volume 6 , Issue 2 (2022)
Pages: 32
Published: November 2022
(This book is a printed edition that was published in OBM Transplantation)
Cover story: A cause-and-effect relationship between PTLD and TMA has raised concerns. Authors share the experience with plasma exchange in the setting of PTLD-associated TMA. Controlled studies are encouraged to more rigorously assess its therapeutic potential in this setting. View this paper.
Volume 6,Issue 2
Plasmapheresis for Thrombotic Microangiopathy Due to a Post-transplant Lymphoproliferative DisorderAbstract We report a case of thrombotic microangiopathy (TMA) diagnosed in the kidney allograft of a 59-year-old woman who had developed plasmacytoma type monomorphic posttransplant lymphoproliferative disorder (PTLD) 30 years after a simultaneous pancreas and kidney transplant. This report demonstrates a rare etiology of TMA in a kidney allograft occurring in association with PTLD-associated monoclonal gammopathy. The main teaching points are: 1) PTLD may be considered in the work-up of a new TMA in the [...] |
An Interview with Prof. Peter SchemmerAbstract InterviewAn Interview with Prof. Peter SchemmerOBM Transplantation Editorial OfficeLIDSEN Publishing Inc., 2000 Auburn Drive, One Chagrin Highlands, Suite 200, Beachwood, OH, USA; E-Mail: transplantation@lidsen.com OBM Transplantation2022, volume 6, issue 2doi:10.21926/obm.transplant.2202159Rec [...] |
Organ System Bleeding in the PLADO TrialAbstract In the multi-institutional platelet dose trial (PLADO Trial), there were 1,077 hematology/oncology patients ≥18 years of age who received at least one platelet transfusion. These patients were analyzed for types and severity of organ system bleeding based on baseline patient characteristics, laboratory assays, primary diagnosis, and type of treatment. Patients were randomly assigned to receive one of three different prophylactic platelet doses for morning platelet counts of ≤10 × 109& [...] |
TOP